Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.

The three price benefit managers jointly administer 80% of all prescriptions in the U.S., the FTC said in the lawsuit.

The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies.

The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in exchange for keeping lower-cost insulin off their lists of approved

UnitedHealth Group division calls the action “baseless” and shows “profound misunderstanding” of drug pricing.

The US Federal Trade Commission sued units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. on Friday, accusing the drug middlemen of engaging in illegal rebate programs that drove up the price of insulin.

The US Federal Trade Commission sued units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. on Friday, accusing the drug middlemen of engaging in illegal rebate programs that drove up the price of insulin.

The Federal Trade Commission has brought an administrative complaint against three of the country's largest pharmacy benefit managers (PBMs), accusing them of engaging in practices that artificially inflated the list price of insulin drugs.

The Federal Trade Commission is suing the three largest prescription drug benefit managers (PBMs) for allegedly driving up insulin prices through anticompe